Five-Year Outcomes From the Randomized, Phase 3 Trials CheckMate 017/057: Nivolumab vs Docetaxel in Previously Treated NSCLC
No Thumbnail Available
Identifiers
Date
2019-10-01
Authors
Gettinger, S.
Borghaei, H.
Brahmer, J.
Chow, L.
Burgio, M.
De Castro Carpeno, J.
Pluzanski, A.
Arrieta, O.
Aren Frontera, O.
Chiari, R.
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier science inc
Metrics
Export
Abstract
Description
MeSH Terms
DeCS Terms
CIE Terms
Keywords
nivolumab, 5-year overall survival, advanced non-small cell lung cancer